Historical Valuation
Purple Biotech Ltd (PPBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.44. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.69
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Purple Biotech Ltd (PPBT) has a current Price-to-Book (P/B) ratio of 18.36. Compared to its 3-year average P/B ratio of 73.76 , the current P/B ratio is approximately -75.11% higher. Relative to its 5-year average P/B ratio of 119.78, the current P/B ratio is about -84.67% higher. Purple Biotech Ltd (PPBT) has a Forward Free Cash Flow (FCF) yield of approximately -94.40%. Compared to its 3-year average FCF yield of -122.14%, the current FCF yield is approximately -22.71% lower. Relative to its 5-year average FCF yield of -82.49% , the current FCF yield is about 14.45% lower.
P/B
Median3y
73.76
Median5y
119.78
FCF Yield
Median3y
-122.14
Median5y
-82.49
Competitors Valuation Multiple
AI Analysis for PPBT
The average P/S ratio for PPBT competitors is 13.31, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PPBT
1Y
3Y
5Y
Market capitalization of PPBT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PPBT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PPBT currently overvalued or undervalued?
Purple Biotech Ltd (PPBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.44. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation methord.
What is Purple Biotech Ltd (PPBT) fair value?
PPBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Purple Biotech Ltd (PPBT) is between NaN to NaN according to relative valuation methord.
How does PPBT's valuation metrics compare to the industry average?
The average P/S ratio for PPBT's competitors is 13.31, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Purple Biotech Ltd (PPBT) as of Jan 10 2026?
As of Jan 10 2026, Purple Biotech Ltd (PPBT) has a P/B ratio of 18.36. This indicates that the market values PPBT at 18.36 times its book value.
What is the current FCF Yield for Purple Biotech Ltd (PPBT) as of Jan 10 2026?
As of Jan 10 2026, Purple Biotech Ltd (PPBT) has a FCF Yield of -94.40%. This means that for every dollar of Purple Biotech Ltd’s market capitalization, the company generates -94.40 cents in free cash flow.
What is the current Forward P/E ratio for Purple Biotech Ltd (PPBT) as of Jan 10 2026?
As of Jan 10 2026, Purple Biotech Ltd (PPBT) has a Forward P/E ratio of -0.39. This means the market is willing to pay $-0.39 for every dollar of Purple Biotech Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Purple Biotech Ltd (PPBT) as of Jan 10 2026?
As of Jan 10 2026, Purple Biotech Ltd (PPBT) has a Forward P/S ratio of 0.00. This means the market is valuing PPBT at $0.00 for every dollar of expected revenue over the next 12 months.